Fermenta Biotech Ltd (FERMENTA) is currently trading at 454.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Fermenta Biotech Limited manufactures and supplies vitamins (notably Vitamin D3), active pharmaceutical ingredients, biocatalysis enzymes, custom premixes, fortified rice kernels and environmental solutions from certified manufacturing sites including Dahej, Kullu and Tirupati, leveraging 75+ years of chemistry expertise and a 100+ person R&D team to serve over 400 customers in 60+ countries. FY26 was a year of operating momentum: consolidated revenue reached a record ₹548 crore (up 14% year‑on‑year), core EBITDA ex real estate rose 44% to about ₹120 crore, profit after tax was ₹70 crore and free cash flow tripled to ₹62 crore, while net debt roughly halved on improved cash generation and steady capex deployment. Fermenta has strengthened its regulatory and innovation moat with a granted plant‑source Vitamin D3 process patent, EDQM CEP for Vitamin D3 100 SD enabling European pharmaceutical access, and commercialization readiness for calcifediol and new enzyme portfolios, aligning product IP, certification and capacity for premium, regulated markets. The company occupies a resilient, diversified market position — claiming a top‑3 global Vitamin D3 manufacturing spot, serving 400+ customers across 60+ countries with low customer concentration (largest customer ~9%, top five ~28%), and a balanced geographic mix across India, Europe and North America that supports durable revenue growth. Strategic priorities emphasize innovation chemistry, green processes and market expansion: board‑approved ₹110 crore Dahej capex to scale plant‑source D3, calcifediol and biocatalysis enzymes, institutional approvals (GAIN/WFP) for fortification tenders and an expanding premix capability to capture preventive nutrition, food fortification and animal nutrition opportunities.

Over the past 52 weeks, Fermenta Biotech Ltd has traded between a low of ₹256.40 and a high of ₹582.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Fermenta Biotech Ltd has a market capitalization of approximately 1,338.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Fermenta Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.01 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,338.82 Cr, Fermenta Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Fermenta Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Fermenta Biotech Ltd is 23.01. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

FSSAI approved Fermenta Biotech’s plant-based Vitamin D3 (Cholecalciferol) product, VITADEE Green®, allowing it to be marketed for food and health supplement use in India.